), a leading RNA medicines company, announced today that preclinical data for a multi-siRNA treatment of Chronic Hepatitis B Virus (HBV), developed in collaboration with
Janssen Pharmaceuticals, Inc., part of the
Janssen Pharmaceutical Companies of Johnson & Johnson, will be presented in a poster at The Liver Meeting, the 67th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held November 11-15, 2016, in Boston.